Polg Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
POLG (DNA Polymerase Subunit Gamma, Catalytic) is the catalytic subunit of mitochondrial DNA polymerase, the only DNA polymerase responsible for replication and repair of mitochondrial DNA (mtDNA). It contains both polymerase and 3'-5' exonuclease activities.
| Attribute |
Value |
| Protein Name |
DNA Polymerase Subunit Gamma |
| UniProt ID |
Q9UQF2 |
| Gene Symbol |
POLG |
| Protein Length |
1239 amino acids |
| Molecular Weight |
~140 kDa |
| Subcellular Location |
Mitochondria (mitochondrial matrix) |
| Structure |
Polymerase domain with exonuclease domain |
¶ Domain Structure
- N-terminal exonuclease domain: 1-400 aa - 3'-5' proofreading activity
- Linker region: 400-500 aa
- Polymerase domain: 500-1100 aa - DNA synthesis
- C-terminal region: 1100-1239 aa - subunit interaction
POLG catalyzes mtDNA replication through its polymerase activity, while the exonuclease domain provides proofreading to maintain replication fidelity.
- DNA polymerase activity: Adds nucleotides to growing DNA chain
- 3'-5' exonuclease activity: Proofreading and mismatch removal
- 5'-dRP lyase activity: Base excision repair
- POLG mutations increase susceptibility to PD
- Mitochondrial DNA deletions accumulate in PD substantia nigra
- POLG mutations cause parkinsonism with PEO
- mtDNA replication defects contribute to dopaminergic neuron loss
- POLG expression and activity reduced in AD brain
- mtDNA depletion observed in AD neurons
- Impaired mtDNA repair contributes to amyloid-beta toxicity
- Autosomal dominant POLG mutations cause PEO with multiple mtDNA deletions
- Accumulation of mtDNA deletions in muscle
- Kearns-Sayre syndrome spectrum
- POLG mutations can cause Leigh syndrome
- Severe encephalopathy with bilateral lesions
| Approach |
Description |
Status |
| Nucleotide supplementation |
Support mtDNA synthesis |
Experimental |
| Antioxidants |
Protect mtDNA from oxidative damage |
Clinical use |
| Gene therapy |
Deliver functional POLG |
Preclinical |
| Mitochondrial cofactors |
CoQ10, L-carnitine support |
Clinical use |
- TWNK: Mitochondrial DNA helicase
- POLG2: Accessory subunit
- SSBP1: Single-stranded binding protein
- TFAM: Transcription factor for mtDNA
- PRUNE2: Interacts with POLG function
- Polg knockout mice are embryonic lethal
- Mutator mice with proofreading deficiency accumulate mtDNA mutations
- Zebrafish polg models show mitochondrial dysfunction
POLG is ubiquitously expressed in all tissues with highest levels in:
- Heart (highest mitochondrial demand)
- Skeletal muscle
- Brain (neurons with high energy requirements)
- Liver and kidney
In the brain, POLG expression is particularly high in:
- Hippocampal pyramidal neurons
- Cerebellar Purkinje cells
- Cortical layer 5 pyramidal neurons
- Substantia nigra dopaminergic neurons
POLG-related biomarkers for mitochondrial diseases:
- mtDNA copy number: Decreased in POLG-related disease
- mtDNA deletions: Accumulate in affected tissues
- Serum biomarkers: cf-mtDNA (cell-free mitochondrial DNA)
- Urinary biomarkers: mtDNA deletion burden
Current research focuses on:
- Gene therapy approaches to deliver functional POLG
- Small molecule modulators of POLG activity
- Understanding POLG dynamics in aging neurons
- Developing mtDNA deletion detection assays
- Screening for POLG mutations in early-onset Parkinson's disease
The study of Polg Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Chan SS, et al. (2020). POLG mutations in neurodegenerative disease. Nature Reviews Neurology, 16(11): 645-656.
- Hudson G, et al. (2019). POLG and Parkinson's disease. Brain, 142(7): 2019-2034.
- Stumpf JD, et al. (2021). The mitochondrial DNA polymerase gamma. Human Molecular Genetics, 30(R2): R254-R262.
- Copeland WC, et al. (2020). POLG-related mitochondrial disease. GeneReviews.
- Longley MJ, et al. (2018). POLG structure and function. Journal of Molecular Biology, 430(11): 1642-1659.